|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
December 2004FeaturesCover Story Making the Case to Managed Care: The Science of Marketing BiologicsMaking a case when biotechs market their products to their most cost-conscious customers — managed care organizations — is far different than what a traditional pharmaceutical company might do with HMO partners. It’s all about the science. Not the cost. Business Partnering: Key to Early-Stage Biotech Survival, But At What Cost?Young companies’ ideas need proof of principle, and devices need a prototype. Most of all, a biotech must find suitable partners to help with early-stage financing and clinical trials. Regulatory Keeping the Ball In BoundsBiotechs take notice of the government’s crackdown on, and willingness to exact heavy fines for, promotion of off-label drug use. Ethics The 5 Most Pressing Ethical Issues in Biotech MedicineThird-party payers, employers, providers, and policy makers face moral dilemmas relative to issues about clinical research, costs, and privacy. Public Health Biotech Steps Into the Vaccine BreachAlthough vaccine manufacturing is extremely tricky and increasingly costly, biotech companies are plowing ahead on the research front. Leading Edge Shaking the Tree of LifeIf we have decoded the human genome, then why continue with the tobacco leaf, the kangaroo, and the dog? Researchers are assembling a “parts list” that will help to define genomics’ role in health and disease. DepartmentsOpeners It’s Not About the RebateSometimes, it’s not about the rebate. Editorial Clinical Trial ReduxDavid B. Nash, MD, MBA, on the future of patient recruitment for clinical trials. Drugs & Diagnostics Road To Developing Regulatory Pathway For Biologic Follow-ons Has Many TurnsWhither a regulatory pathway for biologic follow-ons? Also, FDA approvals and denials, and results of clinical trials. Discourse Biotech Cheers 4 More Years, But Familiar Struggles Still AheadWhat the next four years may bring. Biotech Business Report: Biotechs Are Next Challenge Health Plan Sponsors Will FaceProactive strategies for plan sponsors to control biotech expenditures. In the Pipeline Biotech developing 324 new productsNew survey finds 324 drugs in development for nearly 150 diseases. |
|||||